Nivolumab in NSCLC: Latest evidence and clinical potential

Raghav Sundar; Byoung Chul Cho; Julie R. Brahmer; Ross A. Soo

doi:10.1177/1758834014567470

Nivolumab in NSCLC: Latest evidence and clinical potential

Raghav Sundar, Byoung Chul Cho, Julie R. Brahmer, Ross A. Soo

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

148 Citations (Scopus)

Abstract

New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

Original language	English
Pages (from-to)	85-96
Number of pages	12
Journal	Therapeutic Advances in Medical Oncology
Volume	7
Issue number	2
DOIs	https://doi.org/10.1177/1758834014567470
Publication status	Published - 2015 Mar

Bibliographical note

Funding Information:
RS, BCC and RAS have no conflicts of interest to declare. JBR has received research funding from Merck and BMS, is a paid consultant for Merck and is a compensated advisory board member for BMS.

Funding Information:
RAS is supported by the National Research Foundation, Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative.

All Science Journal Classification (ASJC) codes

Oncology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1177/1758834014567470

Fingerprint Dive into the research topics of 'Nivolumab in NSCLC: Latest evidence and clinical potential'. Together they form a unique fingerprint.

Cite this

@article{3b46844101cd4a88a94a5dda3648ba01,

title = "Nivolumab in NSCLC: Latest evidence and clinical potential",

abstract = "New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.",

author = "Raghav Sundar and Cho, {Byoung Chul} and Brahmer, {Julie R.} and Soo, {Ross A.}",

note = "Funding Information: RS, BCC and RAS have no conflicts of interest to declare. JBR has received research funding from Merck and BMS, is a paid consultant for Merck and is a compensated advisory board member for BMS. Funding Information: RAS is supported by the National Research Foundation, Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative. ",

year = "2015",

month = mar,

doi = "10.1177/1758834014567470",

language = "English",

volume = "7",

pages = "85--96",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

number = "2",

}

TY - JOUR

T1 - Nivolumab in NSCLC

T2 - Latest evidence and clinical potential

AU - Sundar, Raghav

AU - Cho, Byoung Chul

AU - Brahmer, Julie R.

AU - Soo, Ross A.

N1 - Funding Information: RS, BCC and RAS have no conflicts of interest to declare. JBR has received research funding from Merck and BMS, is a paid consultant for Merck and is a compensated advisory board member for BMS. Funding Information: RAS is supported by the National Research Foundation, Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative.

PY - 2015/3

Y1 - 2015/3

N2 - New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

AB - New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84924809260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924809260&partnerID=8YFLogxK

U2 - 10.1177/1758834014567470

DO - 10.1177/1758834014567470

M3 - Review article

AN - SCOPUS:84924809260

VL - 7

SP - 85

EP - 96

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 2

ER -

Nivolumab in NSCLC: Latest evidence and clinical potential

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this